Custom Lucite for Phase I Drug Trial

Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)

Side view of Lucite commemorative celebrating the first patient dosed in the clinical trial of Sorriso's SOR 102 drug.